Angle welcomes research that uses its tech to diagnose prostate cancer

AIM-listed medical company Angle said it welcomes research that will be presented at a conference that uses the company’s technology to diagnose prostate cancer.

At the National Cancer Research Institute annual conference, on 6 November, research will be shown that supports the potential use of its Parsortix cell separation technology as part of a blood test to diagnose and monitor patients with prostate cancer.

Scientists at the Barts Cancer Institute at Queen Mary University in east London, used Parsortix and were able to capture a specific subset of circulating tumour cells from prostate cancer patient blood samples.

The circulating tumour cells, which cannot be captured by traditional systems, are linked to the spread of prostate cancer and could potentially be used to stage the severity of the disease by monitoring the patient.

Founder and chief executive, Andrew Newland, said the presentation will support the adoption of Parsortix as a non-invasive alternative to the biopsy of prostate tissue.

“Biopsy is the current standard of care for men suspected of prostate cancer, and yet 75% to 80% of men enduring a biopsy and running the risk of potentially serious complications, do not have prostate cancer. Less than 10% of biopsied patients have aggressive cancer where treatment is recommended.

He added that Parsortix has the potential to provide the additional staging information to allow physicians to determine which patients require treatment and to provide active monitoring for all prostate cancer patients.

Shares in Angle were up 2.51% to 59.97p at 1003 GMT.